NSCLC

NSCLC
Name	Non-Small Cell Lung Cancer
Synonyms	NSCLC
Field	Oncology, Pulmonology
Symptoms	Cough, Hemoptysis, Dyspnea
Complications	Superior vena cava syndrome, Paraneoplastic syndrome
Causes	Tobacco smoking, Radon, Asbestos
Risks	Air pollution, Family history
Diagnosis	Computed tomography, Biopsy, Positron emission tomography
Treatment	Surgery, Radiation therapy, Chemotherapy, Immunotherapy
Medication	Erlotinib, Osimertinib, Pembrolizumab
Prognosis	Depends on Cancer staging
Frequency	~85% of Lung cancer cases

NSCLC. It represents the most prevalent histological category of Lung cancer, accounting for approximately 85% of all cases. This group of malignancies originates from the epithelial cells lining the airways and is characterized by slower growth and later spread compared to its counterpart, Small-cell lung carcinoma. The management and outlook for patients depend heavily on the specific subtype, stage at diagnosis, and molecular characteristics of the tumor.

Overview

NSCLC encompasses several distinct histological subtypes, primarily Adenocarcinoma, Squamous-cell carcinoma, and Large-cell lung carcinoma. These cancers are frequently associated with prolonged exposure to carcinogens, most notably through Tobacco smoking, and have a significant global health burden. Major institutions like the American Cancer Society and the World Health Organization continuously update classification guidelines, which are critical for guiding therapeutic decisions. The National Cancer Institute supports extensive research into the biology and treatment of these malignancies, which often present in advanced stages due to initially subtle symptoms.

Classification and staging

The classification of NSCLC is formally defined by the World Health Organization and is integral to the TNM staging system maintained by the American Joint Committee on Cancer and the Union for International Cancer Control. Key histological subtypes include Adenocarcinoma, often found in the lung periphery and linked to mutations in genes like EGFR, and Squamous-cell carcinoma, typically central and associated with Tobacco smoking. Staging involves imaging such as Computed tomography and Positron emission tomography, and may include procedures like Endobronchial ultrasound to assess lymph node involvement. The stage determines eligibility for curative Surgery, such as Lobectomy or Pneumonectomy.

Causes and risk factors

The predominant cause of NSCLC is chronic exposure to inhaled carcinogens, with Tobacco smoking being the single most significant risk factor, as highlighted by the Centers for Disease Control and Prevention. Other environmental hazards include exposure to Radon gas, Asbestos fibers, certain heavy metals like Arsenic, and outdoor Air pollution as monitored by the Environmental Protection Agency. Genetic predispositions and a Family history of lung cancer also contribute to risk, with certain populations showing higher incidence rates. Occupational exposures in industries such as Mining and Construction are well-documented hazards.

Diagnosis

Diagnosis typically begins with imaging studies, most commonly a Computed tomography scan of the chest, which may identify a suspicious mass. Subsequent confirmation requires a Biopsy, obtainable through techniques like Bronchoscopy, CT-guided biopsy, or Thoracentesis if Pleural effusion is present. Pathological examination by a Pathologist at an institution like the Mayo Clinic confirms the histological subtype. Advanced molecular testing for mutations in EGFR, ALK, ROS1, and PD-L1 expression is now standard to guide targeted and Immunotherapy options.

Treatment

Treatment strategies are multidisciplinary and depend on stage, patient health, and tumor genetics. Early-stage disease is often treated with curative Surgery, such as a Lobectomy, possibly followed by adjuvant Chemotherapy. For locally advanced cases, a combination of Radiation therapy and Chemotherapy, or Chemoradiotherapy, is standard. Advanced or metastatic disease utilizes systemic therapies, including platinum-based Chemotherapy, Targeted therapy with agents like Osimertinib for EGFR mutations, and Immunotherapy drugs such as Pembrolizumab and Nivolumab. Research from Memorial Sloan Kettering Cancer Center continues to expand treatment paradigms.

Prognosis

The Prognosis varies widely based on the stage at diagnosis, histological subtype, and molecular profile. Early-stage tumors treated with complete Surgical resection have a favorable five-year Survival rate, while metastatic disease has a significantly poorer outlook. The advent of Targeted therapy and Immunotherapy has markedly improved outcomes for specific patient subgroups, as evidenced by clinical trials from organizations like the European Society for Medical Oncology. Overall survival continues to improve due to advances in screening, such as Low-dose computed tomography recommended by the United States Preventive Services Task Force, and personalized treatment approaches.

Category:Lung cancer Category:Respiratory diseases Category:Oncology